Abstract 81P
Background
The NIFTY trial showed that nal-IRI plus 5-FU/LV significantly improved the blinded-independent central review (BICR)- and investigator-assessed progression-free survival (PFS) and overall survival (OS) compared with 5-FU/LV. An updated analysis (data cutoff: 31 DEC 2021) was performed to assess the long-term efficacy outcomes (extension follow-up of 1.3 years). As there was a concern about the large discrepancy rates (30%) between BICR and investigator review in the previous analysis, BICR was performed again by three independent radiologists with more experience in clinical trials and also through external monitoring.
Methods
Pts with > 19 yrs, ECOG PS 0-1, metastatic BTC, and disease progression on prior GemCis were eligible. Pts were randomized 1:1 to nal-IRI plus 5-FU/LV or 5-FU/LV, every 2 weeks. Tumor response was evaluated per RECIST v1.1, every 6 wks.
Results
Between SEP 2018 and FEB 2020, 88 and 86 pts were included in nal-IRI plus 5-FU/LV and 5-FU/LV groups, respectively. With median follow-up of 6.1 mo (IQR 3.5-12.6), median PFS per BICR in nal-IRI plus 5-FU/LV group and 5-FU/LV group was 3.9 mo (95% CI, 2.6-4.7) and 1.5 mo (1.2-1.9), respectively (HR=0.38 [0.26-0.54], p<0.0001); median PFS per investigator review was 3.9 mo (2.7-5.2) and 1.6 mo (1.3-2.2), respectively (HR=0.51 [0.36-0.71], p<0.0001). Median OS was 8.6 mo (5.4-10.5) and 5.3 mo (4.7-7.2), respectively (HR=0.68 [0.48-0.95], p=0.024). ORR was 12.5% and 3.5% per BICR, respectively (p=0.043) and 19.3% and 2.3% per investigator review, respectively (p=0.0002). The discordance rate for tumor progression date between BICR and investigators was 10.7%. In multivariate analyses for prognostic factors, bone mets was associated with poor PFS; male, CA 19-9 > median, elevated CRP, and albumin > median were associated with poor OS; prior GemCis duration > median was associated with better OS.
Conclusions
The survival benefits of 2nd line nal-IRI plus 5-FU/LV versus 5-FU/LV were maintained over an extended follow-up in BTC pts.
Clinical trial identification
NCT03524508.
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
89P - Radiotherapy followed by camrelizumab for unresectable biliary tract cancer: A phase II clinical trial
Presenter: Zhenwei Peng
Session: Poster viewing 02
90P - Feasibility of using tumor-informed circulating tumor DNA (ctDNA)-based testing for patients with anal squamous cell carcinoma
Presenter: Georges Azzi
Session: Poster viewing 02
92P - Safety of liver resection following atezolizumab plus bevacizumab treatment in hepatocellular carcinoma (HCC) patients with macrovascular invasion: A pre-specified analysis of the TALENTop study
Presenter: Huichuan Sun
Session: Poster viewing 02
93P - Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Presenter: Takuji Okusaka
Session: Poster viewing 02
94P - The treatment burden of neoadjuvant carboplatin/paclitaxel versus 5-fluorouracil/cisplatin in combination with radiotherapy for patients with esophageal cancer
Presenter: Chun-Ling Chi
Session: Poster viewing 02
95P - Additional survival follow-up of TACTICS-L: Transcatheter arterial chemoembolization therapy (TACE) in combination strategy with lenvatinib in (LEN) patients with unresectable hepatocellular carcinoma in Japan
Presenter: Yoshitaka Inaba
Session: Poster viewing 02
96P - Preoperative chemotherapy flot vs dox in patients of locally advanced gastric adenocarcinoma
Presenter: POORNIMA DEVI UTHAYAKUMAR
Session: Poster viewing 02
97P - BEAR study: A single-arm, phase II trial of BI-754091 and afatinib for refractory esophageal squamous cell carcinoma
Presenter: Nai-Jung Chiang
Session: Poster viewing 02